JP2000514420A5 - - Google Patents

Download PDF

Info

Publication number
JP2000514420A5
JP2000514420A5 JP1998503444A JP50344498A JP2000514420A5 JP 2000514420 A5 JP2000514420 A5 JP 2000514420A5 JP 1998503444 A JP1998503444 A JP 1998503444A JP 50344498 A JP50344498 A JP 50344498A JP 2000514420 A5 JP2000514420 A5 JP 2000514420A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998503444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000514420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/010898 external-priority patent/WO1997049406A1/en
Publication of JP2000514420A publication Critical patent/JP2000514420A/ja
Publication of JP2000514420A5 publication Critical patent/JP2000514420A5/ja
Pending legal-status Critical Current

Links

JP10503444A 1996-06-25 1997-06-24 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのk―252a誘導体の使用 Pending JP2000514420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2040696P 1996-06-25 1996-06-25
US60/020,406 1996-06-25
PCT/US1997/010898 WO1997049406A1 (en) 1996-06-25 1997-06-24 Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008053174A Division JP4767982B2 (ja) 1996-06-25 2008-03-04 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのk−252a誘導体の使用

Publications (2)

Publication Number Publication Date
JP2000514420A JP2000514420A (ja) 2000-10-31
JP2000514420A5 true JP2000514420A5 (enExample) 2005-02-10

Family

ID=21798468

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10503444A Pending JP2000514420A (ja) 1996-06-25 1997-06-24 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのk―252a誘導体の使用
JP2008053174A Expired - Lifetime JP4767982B2 (ja) 1996-06-25 2008-03-04 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのk−252a誘導体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008053174A Expired - Lifetime JP4767982B2 (ja) 1996-06-25 2008-03-04 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのk−252a誘導体の使用

Country Status (16)

Country Link
US (1) US6184217B1 (enExample)
EP (1) EP0912184B1 (enExample)
JP (2) JP2000514420A (enExample)
CN (1) CN1108799C (enExample)
AT (1) ATE224718T1 (enExample)
AU (1) AU721942B2 (enExample)
BR (1) BR9710693A (enExample)
DE (1) DE69715862T2 (enExample)
DK (1) DK0912184T3 (enExample)
ES (1) ES2184106T3 (enExample)
NO (1) NO317335B1 (enExample)
NZ (1) NZ333441A (enExample)
PT (1) PT912184E (enExample)
RU (1) RU2183959C2 (enExample)
UA (1) UA65542C2 (enExample)
WO (1) WO1997049406A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9068992B2 (en) 2004-06-24 2015-06-30 Biogen Ma Inc. Screening methods for identifying Sp35 antagonists

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CN1329034C (zh) 1998-09-25 2007-08-01 赛福伦公司 预防/治疗感觉毛细胞和耳蜗神经元损伤的药物
NZ511084A (en) 1998-10-13 2004-01-30 Kyowa Hakko Kogyo Kk An agent for treating ophthalmopathy
JP2000290184A (ja) * 1999-04-01 2000-10-17 Kyowa Hakko Kogyo Co Ltd 経鼻投与製剤
US6930125B2 (en) * 2000-01-14 2005-08-16 John F. Hunt Airway alkalinization as a therapy for airway diseases
AU2001261324A1 (en) * 2000-05-08 2001-11-20 Psoriasis Research Institute Psoriasis treatment
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
AR035971A1 (es) * 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
JP2006513187A (ja) * 2002-12-23 2006-04-20 ライナット ニューロサイエンス コーポレイション タキソール誘発性感覚性ニューロパシーを処置するための方法
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
EP1646372A2 (en) * 2003-07-14 2006-04-19 Decode Genetics EHF. Methods of diagnosis and treatment for asthma based on haplotype association
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US20060210553A1 (en) * 2003-07-23 2006-09-21 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation
NZ548857A (en) 2004-02-27 2010-05-28 Lundbeck & Co As H Crystalline forms of a diazocine pharmaceutical compound for Parkinson's and similar conditions
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Lingo抗体または断片を含む組成物
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Lingo‐1拮抗薬及び脱髄障害の治療のための使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) * 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質k―252
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Sf−2370物質ハロゲン化誘導体とその製造法
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質k−252の誘導体
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質k−252の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ucn―01
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質k−252の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 K−252誘導体
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
DE3835842A1 (de) 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
WO1991009034A1 (en) 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質rk−1409、その製造法並びに抗腫瘍剤及び抗炎症剤
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
RU2045575C1 (ru) * 1992-01-29 1995-10-10 Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Рекомбинатная плазмидная днк ppr - tgatg - hil - 1 beta - tsr, обеспечивающая синтез рекомбинантного интерлейкина-1 и штамм escherichia coli - продуцент рекомбинантного интерлейкина-1 бета человека
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ucn−01誘導体
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
GB9215921D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
EP0699204B1 (en) 1993-05-28 1998-04-15 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
AU7000094A (en) 1993-06-17 1995-01-17 Ciba-Geigy Ag Indolocarbazole compound useful as proteinkinase c inhibitor
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9068992B2 (en) 2004-06-24 2015-06-30 Biogen Ma Inc. Screening methods for identifying Sp35 antagonists

Similar Documents

Publication Publication Date Title
JP2000511083A5 (enExample)
JP2000504602A5 (enExample)
JP2000509458A5 (enExample)
JP2000507565A5 (enExample)
JP2000506628A5 (enExample)
JP2000510961A5 (enExample)
JP2001507641A5 (enExample)
JP2000511377A5 (enExample)
JP2000510189A5 (enExample)
JP2000511016A5 (enExample)
JP2000507091A5 (enExample)
JP2000514170A5 (enExample)
JP2000507745A5 (enExample)
JP2000506861A5 (enExample)
JP2000506046A5 (enExample)
JP2000512342A5 (enExample)
JP2000506908A5 (enExample)
JP2000506788A5 (enExample)
JP2000502931A5 (enExample)
JP2000515368A5 (enExample)
JP2000508681A5 (enExample)
JP2000511953A5 (enExample)
JP2000508745A5 (enExample)
JP2001502170A5 (enExample)
JP2000512651A5 (enExample)